Targeted Drug Combo May Change Care for Rare Brain Tumor Craniopharyngioma - Cancer Currents Blog

The latest from the NCI Cancer Currents blog

Having trouble viewing this email? View it as a Web page.

Targeted Drug Combo May Change Care for Rare Brain Tumor Craniopharyngioma 08/10/2023 Treating craniopharyngioma often requires surgery, radiation therapy, or both. But results of a study suggest that, for many, combining the targeted therapies vemurafenib (Zelboraf) and cobimetinib (Cotellic) may substantially delay, or even eliminate, the need for these treatments. You are subscribed to the latest posts from Cancer Currents: An NCI Cancer Research Blog from the National Cancer Institute. Update your subscriptions.

Stay Connected with the National Cancer Institute
Chat with us: LiveHelp  Call us: 1-800-4-CANCER (1-800-422-6237) SUBSCRIBER SERVICES: Manage Subscriptions  |  Help

 

This email was sent to myhcistech.healthnews360@blogger.com using GovDelivery Communications Cloud on behalf of: National Cancer Institute · BG 9609 MSC 9760 · 9609 Medical Center Drive · Bethesda, MD 20892